Peregrine Pharma (PPHM) Reports In-Line Q2 Loss
Tweet
Share
E-mailGet Alerts PPHM Hot Sheet
Join SI Premium – FREE
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported Q2 loss of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $2.83 million versus the consensus estimate of $2.28 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
- IDT Corp. (IDT) Misses Q4 EPS by 3c
- Accenture (ACN) Tops Q4 EPS by 10c, Misses on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
